Unify insights to accelerate drug development and achieve development milestones. Partner with Certara to unlock your pipeline’s potential.
Learn more
Certara collaborates with leading biotech, pharma, and CRO partners to tackle complex challenges, deliver innovation, and shape the future of healthcare.
Learn more
Join a global leader transforming the future of drug development. Explore opportunities to innovate, grow, and make a difference in transforming lives.
Visit careers siteTwenty four hour ammonia profiles and correlates of drug effect were examined in a phase 2 comparison of sodium phenylbutyrate (NaPBA) and glycerol phenylbutyrate (GPB or HPN-100), an investigational drug…
In May 2011, T.J. Smith and B.E. Hillner published an opinion piece in the New England Journal of Medicine titled “Bending the Cost Curve in Cancer Care” (link). In this…
The process of curve stripping is used in both compartmental and non-compartmental analysis. Each pharmacokinetic profile is made up of one or more exponential phases. The “curve stripping” process extracts…
Assess safety and tolerance of intravenous (IV) baclofen using a dog model. Prospective pharmacokinetic study involving 6 adult dogs. Two dogs received baclofen 10 mg oral and IV bolus doses….
Rifampin and carbamazepine have been recommended in the U.S. Food and Drug Administration draft drug interaction guidance as CYP3A4 inducers for clinical drug-drug interaction (DDI) studies. To optimize the dose…
Polycyclic aromatic hydrocarbons (PAHs) are believed to be among the causative agents for lung cancer in smokers. PAHs require metabolic activation for carcinogenicity. One pathway produces diol epoxides that react…
Predicting the magnitude of time-dependent metabolic drug-drug (mDDIs) interactions involving cytochrome P-450 3A4 (CYP3A4) from in vitro data requires accurate knowledge of the inactivation parameters of the inhibitor (KI), kinact)…
UDP-glucuronosyltransferases (UGTs) are critical for the metabolism and clearance of drugs, chemicals, and hormones. The development of UGT1A1 and 1A6 was studied in 50 pediatric liver samples using bilirubin, serotonin…
Clofarabine, a newer purine analog with reduced central nervous system toxicity, may prove advantageous in hematopoietic cell transplantation in patients for whom neurotoxicity is a natural part of disease progression….
TBR-652 is a novel CCR5 antagonist with potent in vitro anti-HIV activity. The objective of this study was to determine the pharmacokinetics (PK) and pharmacodynamics (PD) of TBR-652 in HIV-1-infected,…
© 2025 Certara. All Rights Reserved. | Privacy policy